NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
421 Halland |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 101 | 1.3% | 17 | 0.2% | 7 | 0.1% | . | . | 3 | 0.0% | . | . | 7938 | 98.4% | 8066 | 100.0% |
ASCUS | 217 | 29.7% | 85 | 11.6% | 41 | 5.6% | . | . | 1 | 0.1% | 4 | 0.5% | 383 | 52.4% | 731 | 100.0% |
LSIL | 55 | 25.8% | 47 | 22.1% | 33 | 15.5% | . | . | . | . | . | . | 78 | 36.6% | 213 | 100.0% |
Atypical glandular cells/AGC | 5 | 35.7% | 1 | 7.1% | . | . | 3 | 21.4% | 4 | 28.6% | 1 | 7.1% | . | . | 14 | 100.0% |
Unclear atypia | 3 | 37.5% | 1 | 12.5% | 3 | 37.5% | . | . | 1 | 12.5% | . | . | . | . | 8 | 100.0% |
ASC-H | 15 | 18.1% | 17 | 20.5% | 46 | 55.4% | . | . | 2 | 2.4% | . | . | 3 | 3.6% | 83 | 100.0% |
HSIL | 6 | 11.8% | 13 | 25.5% | 27 | 52.9% | 1 | 2.0% | 3 | 5.9% | . | . | 1 | 2.0% | 51 | 100.0% |
Totalt | 402 | 4.4% | 181 | 2.0% | 157 | 1.7% | 4 | 0.0% | 14 | 0.2% | 5 | 0.1% | 8403 | 91.7% | 9166 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81403 |